UK DIRECTOR DEALINGS SUMMARY: 888 CEO Sells GBP780,000 In Shares
UK DIRECTOR DEALINGS SUMMARY: 888 CEO Sells GBP780,000 In Shares
Read moreUK DIRECTOR DEALINGS SUMMARY: 888 CEO Sells GBP780,000 In Shares
Read moreUK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus
Read moreIN BRIEF: Tiziana To Start Brazil Clinical Trial For Covid-19 Patients
Read more(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Thursday that the capital reduction required for the demerger of StemPrintER Sciences, and to enable the ultimate allotment of Accustem Sciences shares to its shareholders, has been sanctioned by the court.
Read moreUK EARNINGS SUMMARY: City Pub In Signs Of Recovery After Tough Interim
Read moreUK Shareholder Meetings Calendar - Next 7 Days
Read moreIN BRIEF: Tiziana To Kick Off Clinical Study On Foralumab
Read moreTiziana Plans 2020 London IPO Of StemPrintER, SPARE Assets
Read moreIN BRIEF: Tiziana Life Sciences Gets US Patent On TZLS-501 In Covid-19
Read more(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Monday that the United States Patent and Trademark Office (USPTO) has granted a patent for methods and use of fully human monoclonal antibody 'TZLS-501' that recognised both IL-6 receptor (IL-6R) and IL-6 receptor complex with IL-6 (IL-6R/IL-6) for prophylactic and therapeutic intervention for human diseases.
Read moreTiziana Life Sciences Gets US Patent For Milciclib In Cancer
Read moreIN BRIEF: Tiziana Gets US Patent For Foralumab As Crohn's Treatment
Read moreUK TRADING UPDATE SUMMARY: Airtel And Telkom Abort Kenya Combination
Read moreUK TRADING UPDATE SUMMARY: Brickability Recovering Well From Pandemic
Read more(Sharecast News) - Biotechnology company Tiziana Life Sciences has signed agreements with four contract research organisations, it announced on Tuesday, to expedite the clinical development of 'TZLS-501' - a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for the treatment of Covid-19 patients.
Read more